{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:28:19Z","timestamp":1793978899652,"version":"4.8.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["ZYGD23021"],"award-info":[{"award-number":["ZYGD23021"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["23HXFH009"],"award-info":[{"award-number":["23HXFH009"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2021HXBH038"],"award-info":[{"award-number":["2021HXBH038"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20395"],"award-info":[{"award-number":["U23A20395"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22307089"],"award-info":[{"award-number":["22307089"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170375"],"award-info":[{"award-number":["82170375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119257","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:29:25Z","timestamp":1787786965000},"page":"119257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Soluble guanylate cyclase stimulators and activators: Chemistry, biology, and therapeutic advances"],"prefix":"10.1016","volume":"319","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7701-3094","authenticated-orcid":false,"given":"Zeping","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qipu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119257_bib1","first-page":"9","article-title":"Rational drug design, medicinal chemistry, planned serendipity and the impact of automation on the drug discovery process","volume":"15","author":"Connor","year":"1993","journal-title":"J. Automat. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib2","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1080\/14786419.2017.1356838","article-title":"Natural products for human health: an historical overview of the drug discovery approaches","volume":"16","author":"Bernardini","year":"2018","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.ejmech.2026.119257_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1440-1681.2000.03240.x","article-title":"A short history of nitroglycerine and nitric oxide in pharmacology and physiology","volume":"27","author":"Marsh","year":"2000","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejmech.2026.119257_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117363","article-title":"Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure","volume":"242","author":"Gawrys","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/nau.25321","article-title":"Nitric oxide signaling pathways in the normal and pathological bladder: do they provide new pharmacological pathways?\u2014ICI-RS 2023","volume":"43","author":"Chakrabarty","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejmech.2026.119257_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177175","article-title":"Soluble guanylyl cyclase stimulators and activators: promising drugs for the treatment of hypertension?","volume":"987","author":"Gawrys","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib7","first-page":"1669","volume":"vol. 396","author":"Friebe","year":"2023"},{"key":"10.1016\/j.ejmech.2026.119257_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106970","article-title":"Soluble guanylyl cyclase: a novel target for the treatment of vascular cognitive impairment?","volume":"197","author":"Nelissen","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119257_bib9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-019-1584-6","article-title":"Structural insights into the mechanism of human soluble guanylate cyclase","volume":"574","author":"Kang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119257_bib10","article-title":"Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases","volume":"14","author":"Yin","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023596","article-title":"Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells","volume":"6","author":"Hoffmann","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119257_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCRESAHA.109.198234","article-title":"Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation","volume":"105","author":"Meurer","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2026.119257_bib13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201304-0686PP","article-title":"Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension","volume":"6","author":"Klinger","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2026.119257_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-3-642-38664-0_13","article-title":"Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction","volume":"218","author":"Risbano","year":"2013","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119257_bib16","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1111\/bph.15698","article-title":"Soluble GC stimulators and activators: past, present and future","volume":"181","author":"Sandner","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119257_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119257_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1586\/17476348.2015.1106316","article-title":"Riociguat for the treatment of pulmonary hypertension","volume":"9","author":"Granton","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.ejmech.2026.119257_bib20","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with preserved ejection fraction study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2026.119257_bib22","doi-asserted-by":"crossref","first-page":"L755","DOI":"10.1152\/ajplung.00138.2010","article-title":"Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension","volume":"301","author":"Chester","year":"2011","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejmech.2026.119257_bib23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/0091270008322906","article-title":"Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib24","article-title":"Soluble guanylate cyclase modulators\u2014a novel therapeutic approach for diabetic kidney disease, Ren","volume":"47","author":"Xu","year":"2025","journal-title":"Fail."},{"key":"10.1016\/j.ejmech.2026.119257_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fphar.2012.00128","article-title":"Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress","volume":"3","author":"Costell","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib26","doi-asserted-by":"crossref","first-page":"H297","DOI":"10.1152\/ajpheart.00079.2015","article-title":"Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes","volume":"309","author":"Goulopoulou","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejmech.2026.119257_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.119257_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000498896","article-title":"Chronological change of vascular reactivity to cGMP generators in the balloon-injured rat carotid artery","volume":"56","author":"Tawa","year":"2019","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.ejmech.2026.119257_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.838","article-title":"Alteration of the soluble guanylate cyclase system in coronary arteries of high cholesterol diet-fed rabbits","volume":"9","author":"Tawa","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejmech.2026.119257_bib30","doi-asserted-by":"crossref","first-page":"H1565","DOI":"10.1152\/ajpheart.00222.2014","article-title":"Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysm","volume":"307","author":"Martin","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejmech.2026.119257_bib31","doi-asserted-by":"crossref","first-page":"L658","DOI":"10.1152\/ajplung.00189.2009","article-title":"The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice","volume":"297","author":"Weissmann","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejmech.2026.119257_bib32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00383-014-3561-3","article-title":"The soluble guanylyl cyclase activator BAY 60-2770 potently relaxes the pulmonary artery on congenital diaphragmatic hernia rabbit model","volume":"30","author":"RojasMoscoso","year":"2014","journal-title":"Pediatr. Surg. Int."},{"key":"10.1016\/j.ejmech.2026.119257_bib33","article-title":"Redox regulation of cancer stem cells: biology and therapeutic implications","volume":"3","author":"Du","year":"2024","journal-title":"MedComm. Oncol."},{"key":"10.1016\/j.ejmech.2026.119257_bib34","article-title":"Oxidative stress and cellular senescence: roles in tumor progression and therapeutic opportunities","volume":"3","author":"Jin","year":"2024","journal-title":"MedComm. Oncol."},{"key":"10.1016\/j.ejmech.2026.119257_bib35","doi-asserted-by":"crossref","first-page":"18451","DOI":"10.1074\/jbc.RA119.011010","article-title":"Synergistic mutations in soluble guanylyl cyclase (sGC) reveal a key role for interfacial regions in the sGC activation mechanism","volume":"294","author":"Childers","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib36","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1021\/bi9929296","article-title":"Inhibition of soluble guanylate cyclase by ODQ","volume":"39","author":"Zhao","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119257_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.freeradbiomed.2015.01.030","article-title":"Novel insights in mammalian catalase heme maturation: effect of NO and thioredoxin-1","volume":"82","author":"Chakravarti","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119257_bib38","doi-asserted-by":"crossref","first-page":"15259","DOI":"10.1074\/jbc.M114.559393","article-title":"Nitric oxide and heat shock protein 90 activate soluble guanylate cyclase by driving rapid change in its subunit interactions and heme content","volume":"289","author":"Ghosh","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib39","doi-asserted-by":"crossref","first-page":"12880","DOI":"10.1074\/jbc.RA119.009016","article-title":"Heat shock protein 90 regulates soluble guanylyl cyclase maturation by a dual mechanism","volume":"294","author":"Dai","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib40","doi-asserted-by":"crossref","first-page":"8948","DOI":"10.1021\/jm400539d","article-title":"Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics","volume":"56","author":"Rekowski","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib41","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1002\/anie.201302588","article-title":"The chemistry and biology of soluble guanylate cyclase stimulators and activators","volume":"52","author":"Follmann","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.119257_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.niox.2018.03.013","article-title":"Redox regulation of soluble guanylyl cyclase","volume":"76","author":"Shah","year":"2018","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.ejmech.2026.119257_bib43","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/ATVBAHA.119.312725","article-title":"Inhibition of MPO (myeloperoxidase) attenuates endothelial dysfunction in mouse models of vascular inflammation and atherosclerosis","volume":"39","author":"Stanley","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2026.119257_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/CIRCRESAHA.117.310705","article-title":"Cytochrome b5 reductase 3 modulates soluble guanylate cyclase redox state and cGMP signaling","volume":"121","author":"Rahaman","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2026.119257_bib45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/mol.117.109918","article-title":"Irreversible activation and stabilization of soluble guanylate cyclase by the protoporphyrin IX mimetic cinaciguat","volume":"93","author":"Kollau","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-019-1584-6","article-title":"Structural insights into the mechanism of human soluble guanylate cyclase","volume":"574","author":"Kang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119257_bib47","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-021-25617-0","article-title":"Activation mechanism of human soluble guanylate cyclase by stimulators and activators","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119257_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119257_bib49","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0960-894X(01)00073-7","article-title":"NO-independent stimulators of soluble guanylate cyclase","volume":"11","author":"Straub","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119257_bib50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/164_2018_197","article-title":"Soluble guanylate cyclase stimulators and activators","volume":"264","author":"Sandner","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib51","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0968-0896(02)00034-2","article-title":"Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase","volume":"10","author":"Straub","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib52","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cmdc.200900014","article-title":"Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension","volume":"4","author":"Feurer","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119257_bib53","series-title":"Preparation of Pyrimidine Derivatives for Treatment of Cardiovascular Disorders or Erectile Dysfunction","author":"Dusseldorf","year":"2011"},{"key":"10.1016\/j.ejmech.2026.119257_bib54","first-page":"P51","article-title":"Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure, BMC","volume":"9","author":"Mitrovic","year":"2009","journal-title":"Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib55","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119257_bib56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41392-026-02624-5","article-title":"Cyclic guanosine monophosphate-protein kinase G signaling attenuates aortic valve calcification through ULK1-mediated autophagy","volume":"11","author":"Wang","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2026.119257_bib57","series-title":"Bayer Healthcare AG, Azabicyclic Derivatives as Stimulators of Guanylate Cyclase, Their Preparation, Pharmaceutical Compositions, and Use for the Treatment of Cardiovascular Disorders","author":"Schirok","year":"2008"},{"key":"10.1016\/j.ejmech.2026.119257_bib58","series-title":"Preparation of imidazo[2,1-c]-1,2,4-triazoles as Guanylate Cyclase Activators for Treatment of Cardiovascular Diseases","author":"Schirok","year":"2008"},{"key":"10.1016\/j.ejmech.2026.119257_bib59","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1016\/j.bmcl.2011.08.071","article-title":"Acidic triazoles as soluble guanylate cyclase stimulators","volume":"21","author":"Roberts","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119257_bib60","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bmcl.2013.01.028","article-title":"Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b] pyridines as soluble guanylate cyclase stimulators","volume":"23","author":"Griebenow","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119257_bib61","series-title":"Preparation of Substituted imidazo[1,2-a]pyridinecarboxamides and Uses Thereof","author":"Alexandros","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib62","series-title":"Preparation of Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines as Stimulators of Soluble Guanylate Cyclases and Useful for Treating And\/Or Preventing Cardiovascular Diseases","author":"Alexandros","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib63","series-title":"Preparation of heteroaryl-substituted imidazo[1,2-a]pyridines and their Use","author":"Alexandros","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib64","series-title":"Preparation of hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and Their Use as Soluble Guanylate Cyclase Stimulants","author":"Alexandros","year":"2014"},{"key":"10.1016\/j.ejmech.2026.119257_bib65","series-title":"Amino-Substituted imidazo[1,2-a]pyridinecarboxamides as Soluble Guanylate Cyclase Inhibitors and Their Preparation","author":"Alexandros","year":"2014"},{"key":"10.1016\/j.ejmech.2026.119257_bib66","series-title":"Preparation of Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and Uses Thereof","author":"Alexandros","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib67","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1021\/acs.jmedchem.2c02082","article-title":"New generation of sGC stimulators: discovery of Imidazo[1,2-a]pyridine carboxamide BAY 1165747 (BAY-747), a long-acting soluble guanylate cyclase stimulator for the treatment of resistant hypertension","volume":"66","author":"Vakalopoulos","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib68","series-title":"Preparation of Imidazopyridine Compounds as Activators of Soluble Guanylate Cyclase (Sgc)","author":"Toshio","year":"2013"},{"key":"10.1016\/j.ejmech.2026.119257_bib69","series-title":"Preparation of Imidazopyridine Compounds as Sgc Activators","author":"Yushi","year":"2012"},{"key":"10.1016\/j.ejmech.2026.119257_bib70","series-title":"Preparation of aryl- and heteroaryl-substituted imidazo[1,2-a]pyridine-3-carboxamides Useful in Treating And\/Or Preventing Cardiovascular Diseases","author":"Alexandros","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib71","series-title":"Preparation of cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their Use","author":"Alexandros","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib72","series-title":"Preparation of Substituted imidazo[1,2-a]pyridinecarboxamides and their Use","author":"Alexandros","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib73","series-title":"Preparation of Pyrrolopyrimidinones as Soluble Guanylate Cyclase (Sgc) Activators","author":"Linda","year":"2010"},{"key":"10.1016\/j.ejmech.2026.119257_bib74","series-title":"Preparation of triazolo-pyrazinyl Derivatives Useful as Soluble Guanylate Cyclase Activators","author":"Raphaelle","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib75","article-title":"Soluble guanylate cyclase stimulators for the treatment of hypertension: discovery of MK-2947","volume":"21","author":"Brockunier","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119257_bib76","series-title":"Pyrrolopyrimidinone Derivatives as Soluble Guanylate Cyclase Activators and their Preparation","author":"Raghavan","year":"2011"},{"key":"10.1016\/j.ejmech.2026.119257_bib77","series-title":"Substituted Annulated Pyrimidines and Triazines as Guanylate Cyclase and Phosphodiesterase 5 Inhibitors and their Preparation","author":"Markus","year":"2013"},{"key":"10.1016\/j.ejmech.2026.119257_bib78","series-title":"Preparation of trifluoromethyl-substituted ring-fused Pyrimidines and Use Thereof","author":"Markus","year":"2014"},{"key":"10.1016\/j.ejmech.2026.119257_bib79","series-title":"Pyrrolopyrimidinone Derivatives as Soluble Guanylate Cyclase Activators and Their Preparation","author":"Berger","year":"2017"},{"key":"10.1016\/j.ejmech.2026.119257_bib80","series-title":"Preparation of Annelated Pyrimidine Derivatives Useful in the Treatment and Prophylaxis of Cardiovascular Diseases","author":"Alexandros","year":"2013"},{"key":"10.1016\/j.ejmech.2026.119257_bib81","series-title":"Preparation of 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines as Cardiovascular Agents","author":"Alexandros","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib82","series-title":"Pyrrolopyrimidinone Derivatives as Soluble Guanylate Cyclase Activators and Their Preparation","author":"Han","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib83","series-title":"Pyrrolopyrimidinone Derivatives as Soluble Guanylate Cyclase Activators and Their Preparation","author":"Han","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib84","series-title":"Preparation of triazolo-pyrazinyl Derivatives Useful as Soluble Guanylate Cyclase Activators,","author":"Raphaelle","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib85","series-title":"Preparation of imidazo-pyrazinyl Derivatives Useful as Soluble Guanylate Cyclase Activators","author":"Joie","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib86","series-title":"Preparation of imidazo-pyrazinyl Derivatives Useful as Soluble Guanylate Cyclase Activators","author":"Joie","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.656561","article-title":"The CNS-penetrant soluble guanylate cyclase stimulator CY6463 reveals its therapeutic potential in neurodegenerative diseases","volume":"12","author":"Correia","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib88","series-title":"Soluble Guanylate Cyclase (Sgc) Stimulators for Treating Diseases","author":"Robert","year":"2019"},{"key":"10.1016\/j.ejmech.2026.119257_bib89","series-title":"Preparation of Imidazopyrazine Derivatives Useful as Soluble Guanylate Cyclase Activators","author":"Joie","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib90","series-title":"Preparation of Fused Pyrazine Derivatives Useful as Soluble Guanylate Cyclase Stimulators","author":"Alan","year":"2017"},{"key":"10.1016\/j.ejmech.2026.119257_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107170","article-title":"Identification of new multi-substituted 1H-pyrazolo[3,4-c]pyridin-7(6H)-ones as soluble guanylyl cyclase (sGC) stimulators with vasoprotective and anti-inflammatory activities","volume":"144","author":"Kintos","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib92","doi-asserted-by":"crossref","first-page":"11215","DOI":"10.1021\/acs.jmedchem.0c01132","article-title":"Discovery of novel pyrazolo[3,4-b] pyridine derivatives with dual activities of vascular remodeling inhibition and vasodilation for the treatment of pulmonary arterial hypertension","volume":"63","author":"Hu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib93","doi-asserted-by":"crossref","first-page":"19781","DOI":"10.1021\/acs.jmedchem.5c02191","article-title":"Discovery of a novel COS\/H2S-donor hybridized sGC stimulator for alleviating isoproterenol-induced myocardial fibrosis","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib94","series-title":"2-Benzyl, 3-(pyrimidin-2-yl) Substituted Pyrazoles Useful as Sgc Stimulators","author":"Charles","year":"2013"},{"key":"10.1016\/j.ejmech.2026.119257_bib95","series-title":"Preparation of Pyrazolyl Compounds as Therapeutic Sgc (Soluble Guanylate Cyclase) Stimulators","author":"Takashi","year":"2014"},{"key":"10.1016\/j.ejmech.2026.119257_bib96","series-title":"Preparation of Pyrazolylpyrimidine Compounds as Soluble Guanylate Cyclase (Sgc) Stimulators","author":"Allan","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib97","series-title":"Preparation of Thienyl Pyrazolyl Compounds as Therapeutic Sgc (Soluble Guanylate Cyclase) Stimulators","author":"Jamie","year":"2014"},{"key":"10.1016\/j.ejmech.2026.119257_bib98","series-title":"Preparation of Substituted Pyrazolylpyrimidines as Soluble Guanylate Cyclase (Sgc) Stimulators","author":"Takashi","year":"2014"},{"key":"10.1016\/j.ejmech.2026.119257_bib99","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fphar.2020.00419","article-title":"Olinciguat, an oral sGC stimulator, exhibits diverse pharmacology across preclinical models of cardiovascular, metabolic, renal, and inflammatory disease","volume":"11","author":"Zimmer","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib100","series-title":"Phosphorus Prodrugs as Sgc Stimulators","author":"Edward","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119257_bib101","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/acsmedchemlett.5b00479","article-title":"Discovery of IWP-051, a novel orally bioavailable soluble guanylate cyclase stimulator with sustained and dose-dependent hemodynamic effects","volume":"7","author":"Nakai","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119257_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127886","article-title":"Discovery of CYR715: a novel carboxylic acid-containing soluble guanylate cyclase stimulator","volume":"40","author":"Rennie","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119257_bib103","series-title":"Preparation of Substituted Pyrazolopyrimidine Derivatives as Soluble Guanylate Cyclase Stimulators and Therapeutic Uses Thereof","author":"Allen","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119257_bib104","series-title":"Preparation of Oxazolylpyrazole Compounds as Soluble Guanylate Cyclase (Sgc) Stimulators","author":"Edward","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib105","series-title":"Preparation of Imidazole and Pyrazole Derivatives as Soluble Guanylate Cyclase (Sgc) Stimulators","author":"Claude","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119257_bib106","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/jm001034k","article-title":"Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase","volume":"44","author":"Selwood","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib107","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0024-3205(02)02361-5","article-title":"A-350619: a novel activator of soluble guanylyl cyclase","volume":"72","author":"Miller","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.119257_bib108","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1254\/jphs.FPJ06017X","article-title":"Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator","volume":"102","author":"Nakane","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119257_bib109","series-title":"Fused Pyrazole Derivatives as Soluble Guanylate Cyclase (Sgc) Stimulators and their Preparation and Use for the Treatment of Diseases","author":"Joel","year":"2011"},{"key":"10.1016\/j.ejmech.2026.119257_bib110","series-title":"Triazole Derivatives as Sgc Stimulators and their Preparation and Use for the Treatment of Diseases","author":"Kim","year":"2012"},{"key":"10.1016\/j.ejmech.2026.119257_bib111","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-540-68964-5_14","article-title":"NO- and Haem-independent soluble guanylate cyclase activators","volume":"191","author":"Schmidt","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib112","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12931-022-02189-1","article-title":"Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC","volume":"23","author":"Pelster","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2026.119257_bib113","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1124\/mol.105.018747","article-title":"Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase","volume":"69","author":"Schindler","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119257_bib114","series-title":"Preparation of Heterocyclic Compounds as Soluble Guanylate Cyclase Activators for Treating Cardiovascular Diseases","author":"Bittner","year":"2009"},{"key":"10.1016\/j.ejmech.2026.119257_bib115","series-title":"Preparation of 2,6-disubstituted Pyridines as Soluble Guanylate Cyclase Activators","author":"Bouillot","year":"2009"},{"key":"10.1016\/j.ejmech.2026.119257_bib116","series-title":"Preparation of Heterocyclic Compounds as Soluble Guanylate Cyclase Activators","author":"Brenneman","year":"2012"},{"key":"10.1016\/j.ejmech.2026.119257_bib117","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1093\/rheumatology\/keaf109","article-title":"Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis","volume":"64","author":"Kaufman","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2026.119257_bib118","series-title":"Preparation of Thiazole Compounds as Activators of Soluble Guanylate Cyclase","author":"Bouillot","year":"2010"},{"key":"10.1016\/j.ejmech.2026.119257_bib119","series-title":"Preparation of Thiazole Compounds as Activators of Soluble Guanylate Cyclase","author":"Boyer","year":"2009"},{"key":"10.1016\/j.ejmech.2026.119257_bib120","series-title":"Preparation of pyrazole-containing Heterocyclic Compound Derivatives as Soluble Guanylyl Cyclase (Sgc) Activators","author":"Matsunaga","year":"2009"},{"key":"10.1016\/j.ejmech.2026.119257_bib121","series-title":"Preparation of Oxoheterocycles as Soluble Guanylate Cyclase Activators Useful as Cardiovascular Agents","author":"Lampe","year":"2010"},{"key":"10.1016\/j.ejmech.2026.119257_bib122","series-title":"Preparation of Branched 3-phenylpropionic Acid Derivatives as Guanylate Cyclase Activators","author":"Hahn","year":"2012"},{"key":"10.1016\/j.ejmech.2026.119257_bib123","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1167\/iovs.18-23772","article-title":"A novel selective soluble guanylate cyclase activator, MGV354, lowers intraocular pressure in preclinical models, following topical ocular dosing","volume":"59","author":"Prasanna","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2026.119257_bib124","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1021\/acs.jmedchem.8b00007","volume":"61","author":"Ehara","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib125","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the soluble guanylate cyclase activator runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib126","doi-asserted-by":"crossref","first-page":"13474","DOI":"10.1021\/acs.jmedchem.4c01364","article-title":"Discovery and optimization of Hsp110 and sGC dual-target regulators for the treatment of pulmonary arterial hypertension","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119257_bib127","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c03039","article-title":"Design and optimization of LOXL2 and sGC dual-target regulators targeting extracellular matrix dysregulation and vasodilation for the treatment of pulmonary arterial hypertension","volume":"68","author":"Hu","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:05:04Z","timestamp":1793977504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":127,"alternative-id":["S0223523426007026"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119257","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble guanylate cyclase stimulators and activators: Chemistry, biology, and therapeutic advances","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119257"}}